Phase 4 N=100 Syphilis Self-testing to Expand Test Uptake Among Men Who Have Sex With Men (SST)
Syphilis
Primary: Syphilis Tests Undertaken — 29; 37 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=100 Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®
Hepatitis B
Primary: Seroconversion Rate — 47; 46 Participants — p=1
N/A N=21 Mobile Coaching to Improve HPV Vaccine Delivery
HPV Vaccine · Provider Communication Practices · Vaccine Recommendation Practices
Primary: Change in HPV Vaccine Recommendation Quality Score — 23.4; 24.2 score
Phase 2 N=40 A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
COPD
Primary: Part A: Pharmacokinetic Parameter AUC0-12 — 175; 611; 1550; 5860 h*pg/mL
N/A N=9 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix
Cervix Carcinoma
Primary: Feasibility of Acquiring In-vivo High-Resolution Microendoscopy (HRME) Images of Cervix Prior to Conization
Phase 2 N=63 A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Bladder Cancer · Urothelial Carcinoma · Urothelial Carcinoma Bladder
Primary: Complete Response (CR) Rate for UGN-102 Treatment — 65.1 percentage of patients
N/A N=10 Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
AIDS-Related Kaposi Sarcoma · Human Immunodeficiency Virus 1 Positive
Primary: Total Score on Quality of Life Assessed Using Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire — 56.9 score on a scale
Phase 3 N=1,372 Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Complicated Urinary Tract Infection · Acute Pyelonephritis
Primary: Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population — 264; 258 Participants
N/A N=43 Cochlear Implantation in Cases of Single-Sided Deafness
Unilateral Moderate to Profound Hearing Loss · Asymmetric Hearing Loss · Single-Sided Deafness (SSD)
Primary: Change in Word Recognition in Quiet Over Time — 4; 8; 0; 0 percentage of words correctly repeated — p=<0.001
Phase 3 N=4,115 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
Chikungunya Virus Infection
Primary: Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination — 204; 0; 59; 0 Participants
N/A N=41 Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer
Oesophageal Cancer
Primary: Completion Rate — 39 Participants
N/A N=1,094 Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites
Smoking Cessation
Primary: Percentage of Patients With 7-day Sustained Smoking Abstinence Reported in the Patient Survey — 13.0; 13.5 percentage of participants — p=0.865
Phase 4 N=171 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.
Chronic Myeloid Leukemia
Primary: Percentage of Participants With Deep Molecular Response MR4.5 at 24 Months of Study Treatment — 35.3 Percentage of participants
Phase 3 N=892 A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments
Migraine
Primary: Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1 to 12 — -2.1; -4.8; -5.3 days/month — p=<0.0001
Phase 2 N=98 Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Follicular Lymphoma
Primary: Complete Response Rate (CRR) Per Independent Review Committee (IRC) Assessment — 69.1 Percentage of participants